Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 14, 2019 - Issue
Submit an article Journal homepage
237
Views
38
CrossRef citations to date
0
Altmetric
Original Research

Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD

Sohini Ghosh1 Division of Pulmonary Diseases and Critical Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, [email protected]
,
Roy A Pleasants2 Durham VA Medical Center, Durham, NC, USA
,
Jill A Ohar3 Department of Medicine, Section of Pulmonary, Critical Care, Allergy, and Immunology, School of Medicine, Wake Forest University, Winston-Salem, NC, USA
,
James F Donohue1 Division of Pulmonary Diseases and Critical Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, [email protected]
&
M Bradley Drummond1 Division of Pulmonary Diseases and Critical Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, [email protected]Correspondence[email protected]
Pages 585-595 | Published online: 01 Mar 2019

Figures & data

Table 1 Baseline demographics and clinical characteristics

Table 2 Inhaler prescriptions

Figure 1 Percentage of patients within bins of peak inspiratory flow (PIFR), measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®; blue) and R5 high resistance inhaler (Handihaler®; orange).

Figure 1 Percentage of patients within bins of peak inspiratory flow (PIFR), measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®; blue) and R5 high resistance inhaler (Handihaler®; orange).

Figure 2 Distribution of patients with suboptimal peak inspiratory flow (PIFR) stratified by Global Initiative for Obstructive Lung Disease (GOLD) FEV1 severity stage, measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®; blue; suboptimal PIFR <60 L/min) and R5 high resistance inhaler (Handihaler®; orange; suboptimal PIFR <30 L/min).

Figure 2 Distribution of patients with suboptimal peak inspiratory flow (PIFR) stratified by Global Initiative for Obstructive Lung Disease (GOLD) FEV1 severity stage, measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®; blue; suboptimal PIFR <60 L/min) and R5 high resistance inhaler (Handihaler®; orange; suboptimal PIFR <30 L/min).

Figure 3 Repeatability of peak inspiratory flow rate (PIFR) from baseline to 2–4 weeks, measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®; blue dashed line) and R5 high resistance inhaler (Handihaler®; orange solid line).

Figure 3 Repeatability of peak inspiratory flow rate (PIFR) from baseline to 2–4 weeks, measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®; blue dashed line) and R5 high resistance inhaler (Handihaler®; orange solid line).

Table 3 Demographics, clinical characteristics, and DPI use in discordant vs concordant participants

Figure S1 Distribution of peak inspiratory flow rate (PIFR) between female and male participants when measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®).

Figure S1 Distribution of peak inspiratory flow rate (PIFR) between female and male participants when measured against R2 low–medium resistance inhaler (eg, Diskus® and Ellipta®).

Figure S2 Distribution of peak inspiratory flow rate (PIFR) between female and male participants when measured against R5 high resistance inhaler (Handihaler®).

Figure S2 Distribution of peak inspiratory flow rate (PIFR) between female and male participants when measured against R5 high resistance inhaler (Handihaler®).

Figure S3 Correlation between height (x-axis) and In-Check™ Dial (y-axis) with R2 low–medium resistance profile inhaler (eg, Diskus® and Ellipta®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Figure S3 Correlation between height (x-axis) and In-Check™ Dial (y-axis) with R2 low–medium resistance profile inhaler (eg, Diskus® and Ellipta®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Figure S4 Correlation between height (x-axis) and In-Check™ Dial (y-axis) with R5 high resistance inhaler (Handihaler®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Figure S4 Correlation between height (x-axis) and In-Check™ Dial (y-axis) with R5 high resistance inhaler (Handihaler®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Figure S5 Correlation between peak inspiratory flow rate measured by standard spirometer (x-axis) and In-Check™ Dial (y-axis) with R2 low–medium resistance profile inhaler (eg, Diskus® and Ellipta®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Figure S5 Correlation between peak inspiratory flow rate measured by standard spirometer (x-axis) and In-Check™ Dial (y-axis) with R2 low–medium resistance profile inhaler (eg, Diskus® and Ellipta®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Figure S6 Correlation between peak inspiratory flow rate (PIFR) measured by standard spirometer (x-axis) and In-Check™ Dial (y-axis) with R5 high resistance profile inhaler (Handihaler®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Figure S6 Correlation between peak inspiratory flow rate (PIFR) measured by standard spirometer (x-axis) and In-Check™ Dial (y-axis) with R5 high resistance profile inhaler (Handihaler®). Blue line represents fitted line with gray shading 95% CI of fitted line.

Table S1 Repeatability of PIFR in COPD participants

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.